BMY vs. ILMN: Bristol-Myers Squibb vs. Illumina Stock Comparison

Company Profile

Bristol-Myers Squibb (BMY) and Illumina (ILMN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BMY is classified in Pharmaceuticals while ILMN is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Illumina (ILMN) has an aggressive beta of 1.46, indicating higher sensitivity to broad-market moves, while Bristol-Myers Squibb (BMY) is defensive at 0.19 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Bristol-Myers Squibb (BMY) at 44.01% and Illumina (ILMN) at 32.39% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Bristol-Myers Squibb (BMY) at 18.47% and Illumina (ILMN) at 19.72% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Bristol-Myers Squibb (BMY) at 33.79% and Illumina (ILMN) at 20.02% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Bristol-Myers Squibb (BMY) at -0.22% is around its peer norm for revenue growth, while Illumina (ILMN) at -0.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Neither Bristol-Myers Squibb (BMY) nor Illumina (ILMN) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Illumina (ILMN) at 2.63 keeps current ratio within its industry’s typical mid-range, while Bristol-Myers Squibb (BMY) at 1.59 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BMY.

Both balance sheets lean debt-heavy versus peers, but BMY is more stretched: Illumina (ILMN) at 0.74 sits in the higher-leverage quartile and Bristol-Myers Squibb (BMY) at 1.91 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Illumina (ILMN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a yield of 3.99%, ranking against industry peers normally.

Illumina (ILMN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a payout of 55.88%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both Bristol-Myers Squibb (BMY) at 13.78 and Illumina (ILMN) at 36.68 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Bristol-Myers Squibb (BMY) at 2.54 sits in the cheaper P/S ratio quartile while Illumina (ILMN) at 7.10 prices around its industry’s middle — BMY costs less per dollar of sales, though read it alongside growth and margins.

Bristol-Myers Squibb (BMY) at 5.43 is valued about in line with its industry on P/B ratio, while Illumina (ILMN) at 10.30 carries an above-peer premium to book — ILMN is pricier on assets.

Valuation Metrics